The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy,...) in patients with pancreatic adenocarcinoma. The effectiveness and tolerance of these treatments in current practice is also evaluated.
Patient with histologically confirmed pancreatic adenocarcinoma.
Disease at a resectable, borderline, locally advanced, initially metastatic, or recurrent stage after surgery
Diagnosis between January 1, 2003, and December 31, 2030.
First-line treatment with chemotherapy and/or radiotherapy and/or clinical trials.
Patient under guardianship, curatorship, or judicial protection.
Pregnant or breastfeeding women.
Any medical, psychological, or social situation that could prevent compliance with the protocol as assessed by the investigator.
Refusal to participate in the study